Advertisement
MBOT vs RCEL
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MBOT is a Hold and RCEL is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MBOT’s FA Score shows that 0 FA rating(s) are green whileRCEL’s FA Score has 0 green FA rating(s).
- MBOT’s FA Score: 0 green, 5 red.
- RCEL’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MBOT’s TA Score shows that 5 TA indicator(s) are bullish while RCEL’s TA Score has 6 bullish TA indicator(s).
- MBOT’s TA Score: 5 bullish, 4 bearish.
- RCEL’s TA Score: 6 bullish, 5 bearish.
Price Growth
MBOT (@Medical/Nursing Services) experienced а +0.58% price change this week, while RCEL (@Medical/Nursing Services) price change was -4.56% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.50%. For the same industry, the average monthly price growth was -7.49%, and the average quarterly price growth was -17.67%.
Reported Earning Dates
MBOT is expected to report earnings on Aug 18, 2026.
RCEL is expected to report earnings on Aug 06, 2026.
Industries' Descriptions
@Medical/Nursing Services (+2.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| MBOT | RCEL | MBOT / RCEL | |
| Capitalization | 116M | 135M | 86% |
| EBITDA | -16M | -37.7M | 42% |
| Gain YTD | -14.000 | 27.536 | -51% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 105K | 72.3M | 0% |
| Total Cash | 72.5M | 14.3M | 507% |
| Total Debt | 898K | 48.1M | 2% |
MBOT | RCEL | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 92 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 49 Fair valued | 63 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 100 | |
PRICE GROWTH RATING 1..100 | 73 | 69 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MBOT's Valuation (49) in the Biotechnology industry is in the same range as RCEL (63) in the null industry. This means that MBOT’s stock grew similarly to RCEL’s over the last 12 months.
MBOT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RCEL (100) in the null industry. This means that MBOT’s stock grew similarly to RCEL’s over the last 12 months.
MBOT's SMR Rating (98) in the Biotechnology industry is in the same range as RCEL (100) in the null industry. This means that MBOT’s stock grew similarly to RCEL’s over the last 12 months.
RCEL's Price Growth Rating (69) in the null industry is in the same range as MBOT (73) in the Biotechnology industry. This means that RCEL’s stock grew similarly to MBOT’s over the last 12 months.
RCEL's P/E Growth Rating (100) in the null industry is in the same range as MBOT (100) in the Biotechnology industry. This means that RCEL’s stock grew similarly to MBOT’s over the last 12 months.
| MBOT | RCEL | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| Stochastic ODDS (%) | 3 days ago 77% | 3 days ago 78% |
| Momentum ODDS (%) | 3 days ago 89% | 3 days ago 86% |
| MACD ODDS (%) | 3 days ago 79% | 3 days ago 88% |
| TrendWeek ODDS (%) | 3 days ago 77% | 3 days ago 82% |
| TrendMonth ODDS (%) | 3 days ago 81% | 3 days ago 80% |
| Advances ODDS (%) | 13 days ago 72% | 14 days ago 76% |
| Declines ODDS (%) | 5 days ago 84% | 5 days ago 80% |
| BollingerBands ODDS (%) | 3 days ago 79% | 3 days ago 76% |
| Aroon ODDS (%) | 3 days ago 86% | 3 days ago 87% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| PIEIX | 39.89 | 0.81 | +2.07% |
| Principal Glb Emerging Markets Inst | |||
| EMRSX | 25.03 | 0.48 | +1.96% |
| JPMorgan Emerging Mkts Rsrch Enh Eq R6 | |||
| SSMAX | 11.04 | -0.02 | -0.18% |
| SEI Small/Mid Cap Equity A (SIIT) | |||
| POIRX | 14.40 | -0.09 | -0.62% |
| Polen International Growth Investor | |||
| PISOX | 15.90 | -0.10 | -0.63% |
| Columbia Pyrford International Stk Ins 2 | |||